CAR-NK RESEARCH - A PROMISING DIRECTION  OF IMMUNE THERAPIES AGAINST CANCER

Trần Thị Thanh Hương

doi:10.34238/tnu-jst.5111

CAR-NK RESEARCH - A PROMISING DIRECTION OF IMMUNE THERAPIES AGAINST CANCER

About this article

Received: 04/10/21 Revised: 20/12/21 Published: 12/01/22

Authors

Tran Thi Thanh Huong , TNU - University of Information and Communication Technology

Abstract

Today, scientists are always trying to find valuable applications new methods based on free in-body service providers. NK is a very important component of the immune system, we can kill cancer cells without induction. However, cancer cells use a variety of tactics to experiment, creating the immune system's failure to block the application. So, they used gene editing technology to introduce CAR - a beneficiary material into NK, which enhances the anti-tumor activity of NK. The objective of this paper is to provide information on the structure of CAR, commonly used NK sources, and methods of CAR conversion and activation in NK to create a complete CAR-NK. The research method of the article is a synthesis of articles on CAR-NK generation methods. The results we obtained are as follows: CAR has a structure of 3 regions, commonly used NK sources are NK92 and PBMC lines; there are two ways to transfer CAR into NK: viral loading and transduction; user to be used to active CAR in NK to CAR-NK has a stronger anti-tumor effect. Clinical application of CAR-NK will become a promising weapon in the fight against cancer.

Keywords

Cell; Immunity; Activated; Tumor; Cytokines

Full Text:

PDF (Tiếng Việt)

References

[1] J. North et al., “Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation,” Jornal of Immunology, vol. 178, pp. 85-94, 2007.

[2] A. M. Abel et al., “Natural killer cells: development, maturation, and clinical utilization,” Frontiers Immunology, vol. 9, pp. 1860-1869, 2018.

[3] K. Rezvani et al., “Engineering natural killer cells for cancer immunotherapy,” Moleculer Therapy, vol. 25, no. 8, pp. 1769-1781, 2017.

[4] H. Fujisaki et al., “Expansion of highly cytotoxic human natural killer cells for cancer cell therapy,” Cancer Research, vol. 69, pp. 4010-4017, 2009.

[5] D. A. Lee “Regulatory considerations for NK cells used in human immunotherapy applications,” Methods in Molecular Biology, vol. 7, pp. 347-361, 2016.

[6] W. Glienke, R. Esser, C. Priesner, J. D. Suerth, A. Schambach, W. S. Wels, M. Grez, S. Kloess, L. Arseniev, and U. Koehl, “Advantages and applications of CAR-expressing natural killer cells,” Frontiers Pharmacology, vol. 6, pp. 18-21, 2015.

[7] M. Luevano, A. Madrigal, and A. Saudemont, “Transcription factors involved in the regulation of natural killer cell development and function: an Update,” Frontiers Immunology, vol. 3, pp. 315-319, 2012.

[8] L. Boissel, H. Klingemann, J. Khan, and P. Soon-Shiong, “Intra-tumor injection of CAR-engineered NK cells induces tumor regression and protection against tumor re-challenge,” Blood, vol. 5, pp. 128-466, 2016.

[9] J. Chu, Y. Deng, D. M. Benson, S. He, T. Hughes, J. Zhang, Y. Peng, H. Mao, L. Yi, and K. Ghoshal, “CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma,” Leukemia, vol. 28, pp. 917-927, 2014.

[10] X. Tang et al., “First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia,” Cancer Research, vol. 8, pp. 1083-1089, 2018.

[11] F. Cichocki, B. Grzywacz, and J. S. Miller, “Human NK cell development: one road or many?” Frontiers Immunology, vol. 10, pp. 2075-2078, 2019.

[12] M. A. Geller and J. S. Miller, “Use of allogeneic NK cells for cancer immunotherapy,” Immunotherapy, vol. 3, pp.1445-1459, 2011.

[13] S. Oelsner, M. E. Friede, C. Zhang, J. Wagner, S. Badura, P. Bader, E. Ullrich, O. G. Ottmann, H. Klingemann, T. Tonn, and W. S. Wels, “Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma,” Cytotherapy, vol. 19, pp. 235-249, 2017.

[14] L. Ruggeri et al., “Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation,” Blood, vol. 94, no. 1, pp. 333-339, 1999.

[15] T. Tonn, D. Schwabe, H. G. Klingemann, S. Becker, R. Esser, U. Koehl, M. Suttorp, E. Seifried, O. G. Ottmann, and G. Bug, “Treatment of patients with advanced cancer with the natural killer cell line NK-92,” Cytotherapy, vol. 15, pp. 1563-1570, 2013.

[16] M. J. Smyth et al., “Activation of NK cell cytotoxicity,” Mol Immunol, vol. 42, pp. 501-510, 2005.

[17] C. Chabannon et al., “Manufacturing natural killer cells as medicinal products,” Frontiers Immunology, vol. 7, pp. 500-504, 2016.

[18] P. Berraondo et al., “Cytokines in clinical cancer immunotherapy,” Bristish Jornal Cancer, vol. 120, pp. 06-15, 2019.

[19] A. Cerwenka and L. L. Lanier, “Natural killer cell memory in infection, inflammation and cancer,” Nature Review Immunology, vol. 16, pp. 112-123, 2016.

DOI: https://doi.org/10.34238/tnu-jst.5111

Refbacks

There are currently no refbacks.



Remember me